Claim Ledger
33% answered
Did management answer the analysts?
12 analyst questions audited, 6 evaded or deflected.
View Claim Ledger →
Divi's Laboratories — Q2 FY25
Divis Labs reported a strong Q2 FY25 with PAT surging 46.6% YoY to INR 510 Cr, driven by robust custom synthesis demand and operational efficiencies.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Divis Labs reported a strong Q2 FY25 with PAT surging 46.6% YoY to INR 510 Cr, driven by robust custom synthesis demand and operational efficiencies. Revenue grew 22.5% YoY to INR 2,444 Cr (total income), with generics facing pricing pressure but volume growth offsetting. The company is investing in GLP-1 peptide fragments, contrast media, and Unit 3 greenfield (production starting Dec 2024). Guidance includes a 20-30% YoY volume increase in contrast media and new generic launches from 2026. Risks include sustained generic pricing pressure and Red Sea logistics disruptions.
डिविस लैब्स ने दूसरी तिमाही में शानदार प्रदर्शन किया। कंपनी का मुनाफा पिछले साल की तुलना में 46.6% बढ़कर 510 करोड़ रुपये हो गया। इसकी वजह है कस्टम सिंथेसिस (ग्राहकों के लिए खास केमिकल बनाना) की मजबूत मांग और काम करने के तरीके में सुधार। कुल आमदनी 22.5% बढ़कर 2,444 करोड़ रुपये हुई। जेनेरिक दवाओं पर कीमत का दबाव है, लेकिन ज्यादा बिक्री से इसकी भरपाई हो रही है। कंपनी नई दवाओं (GLP-1, कंट्रास्ट मीडिया) और नए कारखाने में निवेश कर रही है। कंट्रास्ट मीडिया की बिक्री 20-30% बढ़ने का अनुमान है। 2026 से नई जेनेरिक दवाएं आएंगी। जोखिम: जेनेरिक दवाओं पर कीमत का दबाव और लाल सागर के रास्ते में आपूर्ति में रुकावट।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Risks
4 risks
Risk Intelligence
Sustained generic pricing pressure
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Exports as % of sales (H1)
87%
N/A
Exports remained high at 87% of total sales revenue for H1 FY25.
Generics to CS mix (H1)
49:51
N/A
Product mix between generics and custom synthesis was 49% and 51% respectively for H1.
Constant currency growth (H1)
21%
N/A
Constant currency revenue growth for H1 FY25 was 21%.
Contrast media volume growth guidance
20-30% YoY
+20-30% YoY
Management guided for 20-30% annual volume increase in contrast media.
What Changed vs Last Quarter
NEW
Unit 3 commercial production to start December 2024
Phase-wise production at the 200-acre greenfield Kakinada facility will begin in December 2024, initially focusing on backward integration and regulatory qualifications.
NEW
Contrast media volume growth of 20-30% YoY
Management expects year-on-year volume increase of 20-30% in contrast media, driven by long-term contracts and new qualifications.
NEW
New generic launches from 2026 onwards
Multiple generic products are advancing towards customer qualifications and regulatory approvals, with revenue contributions expected from 2026.
UPDATED
FY25 total CapEx of ~INR 1,600 Cr
Total capital expenditure for FY25, including Kakinada, is expected to be around INR 1,600 crores, with INR 1,000 crores remaining to be spent.
DROPPED
Double-digit revenue growth expected for FY25
Management reiterated confidence in achieving double-digit growth for the full year, driven by both generics and custom synthesis.
DROPPED
Kakinada Unit 3 phase I production to begin gradually in FY25
The 200-acre phase I of the greenfield expansion will start production during FY2024-25, with regulatory approvals and customer filings taking 1-2 years for full commercialization.
DROPPED
New generic products to commercialize in FY26
Emerging generic products with DMF filings planned for completion in the next few months will be commercialized in FY2026, targeting patent expiries in 2025-27.
NEW RISK
Sustained generic pricing pressure
Pricing pressure across the generic portfolio continues, with no clear timeline for stabilization; management hopes for normalization in 6-12 months.
NEW RISK
Raw material cost volatility
While raw material prices have stabilized, they remain sensitive to Middle East developments and crude oil fluctuations, posing a risk to margins.
NEW RISK
Unit 3 ramp-up and regulatory approvals
The greenfield Unit 3 will take time to achieve regulatory approvals and full utilization, with initial production focused on non-regulatory products.
RISK GONE
Pricing pressure in large-volume generics
Persistent price erosion in products like naproxen, gabapentin, and dextromethorphan may continue for 12-15 months due to channel destocking, impacting revenue growth.
RISK GONE
Dependence on custom synthesis project wins
While BIOSECURE Act opportunities are emerging, the timing and conversion of phase II/III molecules into commercial revenue remain uncertain and may take years.
RISK GONE
Nutraceutical segment stagnation
Nutraceutical revenue was flat YoY at INR 178 crore; management attributes it to quarterly lumpiness, but sustained weakness could weigh on overall growth.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q1 FY25
While BIOSECURE Act opportunities are emerging, the timing and conversion of phase II/III molecules into commercial revenue remain uncertain and may take years.
Mentioned in Q1 FY24, Q3 FY24
Management expects double-digit revenue growth for FY25, driven by custom synthesis ramp-up and new generic launches.
Fast read
Guidance and risk preview
Phase-wise production at the 200-acre greenfield Kakinada facility will begin in December 2024, initially focusing on backward integration and regu...
Pricing pressure across the generic portfolio continues, with no clear timeline for stabilization; management hopes for normalization in 6-12 months.
View Risks →